B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
KYTX
Kyverna TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$6.80
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+86.1
Score
AI commentary
Clinical headlines were constructive, but the initial September 24 trading gain reversed and the October 1 $6.52 anchor was below the September 23 $7.07 close. This is not evidence that the trial failed. No verified incremental September 29 presentation analysis or dependable post-data estimate revision was available. Social, options, short-interest and employee figures above are unavailable; zeros are placeholders, not neutral readings. Historical prices
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-23eventFull one-year SPS dataset at MS TorontoHigh impact
Kyverna plans to present the full KYSA-8 dataset on October 21–23. Its reported 12-month follow-up showed a 49% median improvement in timed walking among 26 patients, but the single-arm sample limits certainty about durability and regulatory interpretation. [#8-K-2026-09-24] Kyverna release
2026-12-31eventComplete rolling SPS BLA submissionHigh impact
Management says the miv-cel submission remains on track for completion in Q4 2026 and intends to include the one-year data. Completion would advance the regulatory case, not establish FDA acceptance or approval. [#SEC-8K-2026-08-11] [#8-K-2026-09-24] Kyverna release
2027-06-30catalystPhase 3 gMG enrollment and funding executionHigh impact
Kyverna targets completion of KYSA-6 Phase 3 enrollment by mid-2027. The seven-patient Phase 2 follow-up was encouraging but cannot establish a randomized Phase 3 outcome. June 30 cash and marketable securities were $199.4 million; the projected runway into 2028 includes available loan draws. [#SEC-8K-2026-08-11] [#8-K-2026-09-24] Kyverna release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology